Halozyme Therapeutics Inc.

(HALO) Trade

By |

Profile

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Contact Information

Website: www.halozyme.com
Email: ir@halozyme.com
Main Phone: +1 858 794-8889
Address: 11388 Sorrento Valley Road
Address 2: Unit 200
State: CA
City / Town: San Diego
Country: USA
Postal Code: 92121

Issuer Information

Exchange: NGS
CEO: Helen I. Torley
Employees: 255
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)
$ 15.25 $ -0.45 (-2.87%)
Last Price 15.25 Change $ -0.45 Change % -2.87 Tick N/A
Bid 15.28 Bid Size 1,600.00 Ask 19.94 Ask Size 300.00
Open 15.78 High 15.91 Low 15.20 Prev Close 15.70
Last Trade Volume 453,706 52 Wk Hi 21.48 52 Wk Low 14.33
Market Cap 2.2 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 144,557,543.00 EPS (TTM) 0.36 PE Ratio 43.60 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 10 31
Number of Buys 8 20
Number of Sells 2 11
Net Activity 68007 -1263509
Last 10 Buys Shares
Laurie Stelzer 1,000
Kathryn E. Falberg 1,000
Kathryn E. Falberg 1,000
Robert L. Engler 1,000
James P. Shaffer 1,000
Kathryn E. Falberg 1,000
Kenneth J. Kelley 1,000
Gregory I. Frost 1,000
Randal J. Kirk 1,000
Randal J. Kirk 1,000
Last 10 Sell Shares
Kenneth J. Kelley 1,000
Harry J. Leonhardt 1,000
Harry J. Leonhardt 1,000
Harry J. Leonhardt 1,000
Harry J. Leonhardt 1,000
Harry J. Leonhardt 1,000
Kenneth J. Kelley 1,000
Robert L. Engler 1,000
Robert L. Engler 1,000
John S. Patton 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 33 33 33 33
Low Target Price Estimate 9 9 9 9
Mean Target Price Estimate 20.17 20.17 20.17 20.17
Standard Deviation 7.7 7.7 7.7 7.7
Date of Most Recent Estimate 05/11/18 05/11/18 05/11/18 05/11/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 3 3 5 5
Moderate Buy 0 0 0 0
Hold 1 1 3 3
Moderate Sell 1 1 1 1
Strong Sell 1 1 0 0
Mean Rec. 2.5 2.5 2 2